

Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios
International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO, CANCER GENOMICS and PROTEOMICS.
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2010 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

The Role of Inflammation in Patients with Intraductal Mucinous Neoplasm of the Pancreas and in those with Pancreatic Adenocarcinoma. R. PEZZILLI, M.M. CORSI, A. BARASSI, A.M. MORSELLI-LABATE, G. DOGLIOTTI, R. CASADEI, R. CORINALDESI, G. MELZI D'ERIL (<i>Bologna; Milan, Italy</i>)	3801
Delayed Elimination of Methotrexate Associated with Co-Administration of Proton Pump Inhibitors. R. SANTUCCI, D. LEVÊQUE, A. LESCOUTE, V. KEMMEL, R. HERBRECHT (<i>Strasbourg, France</i>).....	3807
Randomized Follow-up Study of Resected NSCLC Patients: Conventional <i>versus</i> ¹⁸ F-DG Coincidence Imaging. J. MONTEIL, A. VERGNENÈGRE, F. BERTIN, F. DALMAY, S. GAILLARD, F. BONNAUD, B. MELLONI (<i>Limoges, France</i>).....	3811
Phase II Study of Neoadjuvant Gemcitabine, Pegylated Liposomal Doxorubicin, and Docetaxel in Locally Advanced Breast Cancer. A. GRAZIA, M. SIMONE, B. LUCIA, C. ALESSANDRO, B. FERNANDO, Z. GIORGIO, Z. STEFANIA, M. ALBERTO, P. DAVIDE (<i>Padova, Italy</i>)	3817
Psychological Response to Cancer: Role of 5-HTTLPR Genetic Polymorphism of Serotonin Transporter. G. SCHILLANI, E. MARTINIS, M.A. CAPOZZO, D. ERA, T. CRISTANTE, G. MUSTACCHI, M.A. CONTE, M. DE VANNA, L. GRASSI, T. GIRALDI (<i>Trieste; Ferrara, Italy</i>)	3823
Efficacy of S-1 in Patients with Capecitabine-resistant Breast Cancer–Japan Breast Cancer Research Network (JBCRN) 04-1 Trial. D. YAMAMOTO, S. IWASE, H. YOSHIDA, Y. KURODA, C. YAMAMOTO, K. KITAMURA, H. ODAGIRI, Y. NAGUMO (<i>Osaka; Tokyo; Fukuoka; Hirosaki, Japan</i>)	3827
Optimal Cutoff Points of CYFRA21-1 for Survival Prediction in Non-small Cell Lung Cancer Patients Based on Running Statistical Analysis. H. TAKAHASHI, K. KURISHIMA, H. ISHIKAWA, K. KAGOHASHI, M. KAWAGUCHI, H. SATOH (<i>Tsukuba, Ibaraki, Japan</i>)	3833
Combined Chemotherapy with Gemcitabine and Cisplatin for Metastatic Urothelial Carcinomas in Patients 80 Years of Age and Over. N. TANJI, T. FUKUMOTO, N. MIURA, Y. YANAGIHARA, K. AZUMA, T. SASAKI, T. NISHIDA, T. KIKUGAWA, K. SHIMAMOTO, K. AOKI, M. YOKOYAMA (<i>Toon, Ehime, Japan</i>)	3839
Autologous Stem Cell Transplantation for Patients with Acute Promyelocytic Leukemia in Second Molecular Remission. F. FERRARA, O. FINIZIO, T. IZZO, C. RICCARDI, C. CRISCUOLO, A. CARBONE, E. BORLENGHI, G. ROSSI (<i>Naples; Brescia, Italy</i>)	3845
Errata	3851
* Reviews (pages 3223, 3233, 3675, 3683, 3693)	

Targeted Therapy for Ewing's Sarcoma: Significance of Heterogeneity. A.C.M. VAN DE LUIJTGAARDEN, W.T.A. VAN DER GRAAF, I. OTTE-HÖLLER, H.W.B. SCHREUDER, Y.M.H. VERSLEIJEN-JONKERS, P.J. SLOOTWEG (<i>Nijmegen, Netherlands</i>)	3715
Importance of Erythropoietin Receptor Expression in Tumour Tissue for the Clinical Course of Breast Cancer. B. VOLGGER, K. KURZ, K. ZÖSCHG, I. THEURL, A. CIRESA-KÖNIG, C. MARTH, G. WEISS (<i>Innsbruck, Austria</i>)	3721
Long-Term Death Rate in Uterine Clear Cell Carcinoma and Uterine Papillary Serous Carcinoma. B. LINDAHL, J. PERSSON, J. RANSTAM, R. WILLÉN (<i>Lund; Uppsala, Sweden</i>)	3727
Pattern of Failures and Clinical Outcome of Patients with Locally Advanced Cervical Cancer Treated with a Tailored Integrated Therapeutic Approach. A. GADDUCCI, M.G. FABRINI, F. PERRONE, B. MANFREDI, A. FANUCCHI, C. LALISCIA, C. BARSOTTI, V. SCOTTI, A.R. GENAZZANI, C. GRECO (<i>Pisa, Italy</i>)	3731
Combination Therapy with VP16 and Ethinylestradiol for Hormone-Refractory Prostate Cancer: Good Response with Tolerability. H. AZUMA, T. INAMOTO, K. TAKAHARA, N. IBUKI, K. KOYAMA, S. UTIMOTO, Y. FUJISUE, H. UEHARA, K. KOMURA, H. NOMI, T. UBAI, Y. KATSUOKA (<i>Takatsuki, Osaka, Japan</i>)	3737
Surface-bound TGF- β 1 on Effusion-derived Exosomes Participates in Maintenance of Number and Suppressive Function of Regulatory TCells in Malignant Effusions. J. WADA, H. ONISHI, H. SUZUKI, A. YAMASAKI, S. NAGAI, T. MORISAKI, M. KATANO (<i>Fukuoka, Japan</i>)	3747
Feasibility and Efficacy of Combination Chemotherapy with S-1 and Fractional Cisplatin for Advanced Gastric Cancer. T. TAKAHASHI, Y. SAIKAWA, H. TAKAISHI, H. TAKEUCHI, N. WADA, T. OYAMA, R. NAKAMURA, Y. KITAGAWA (<i>Tokyo, Japan</i>)	3759
A Case of Esophageal Cancer Showing Complete Remission of Nephrotic Syndrome after Esophagectomy. Y. NARITAKA, S. ASAKA, A. MIYAKI, N. ISOHATA, T. SHIMAKAWA, K. YAMAGUCHI, T. KATSUBE, T. MURAOKA, S. SHIOZAWA, K. YOSHIMATSU, K. OGAWA (<i>Tokyo, Japan</i>)	3763
Desmoplastic Small Round Cell Tumour Successfully Treated with Caffeine-assisted Chemotherapy: A Case Report and Review of the Literature. S. MIWA, S. KITAMURA, T. SHIRAI, K. HAYASHI, H. NISHIDA, A. TAKEUCHI, T. NOJIMA, H. TSUCHIYA (<i>Kanazawa; Kahoku, Japan</i>)	3769
Dermatofibrosarcoma Protuberans: A Case Series of 16 Patients Treated in a Single Institution with Literature Review. M. ARCHONTAKI, D.P. KORKOLIS, N. ARNOGIANNAKI, C. KONSTANTINIDOU, S. GEORGOPOULOS, P. DENDRINOS, G. ZARKADAS, G. KOKKALIS (<i>Athens, Greece</i>)	3775
Re-irradiation of Head and Neck Cancer—Impact of Total Dose on Outcome. S. JANSSEN, M. BAUMGARTNER, M. BREMER, A. WARSZAWSKI, M. STIEVE, A. ECKARDT, J.-H. KARSTENS, A. MEYER (<i>Hannover, Germany</i>)	3781
Evaluation of FDG–PET for Detecting Lymph Node Metastasis in Uterine Corpus Cancer. M. KLAR, P.T. MEYER, K. HANCKE, I. BRINK, M. ORLOWSKA-VOLK, G. GITSCH, D. DENSCHLAG (<i>Freiburg, Germany</i>)	3787
Complete Response Obtained by Bortezomib plus Dexamethasone in a Patient with Relapsed Multiple Myeloma with Multiple Plasmacytomas. T. FUKUSHIMA, T. NAKAMURA, M. MIKI, T. SAKAI, H. IWAO, A. NAKAJIMA, T. SAWAKI, Y. FUJITA, M. TANAKA, Y. MASAKI, Y. HIROSE, H. UMEHARA (<i>Ishikawa, Japan</i>)	3791
Functional Results after Giant Cell Tumor Operation near Knee Joint and the Cement Radiolucent Zone as Indicator of Recurrence. K. KAFCHITSAS, B. HABERMANN, D. PROSCHEK, A. KURTH, C. EBERHARDT (<i>Mainz; Hanau, Germany</i>)	3795

Comparison of the Apoptosis-inducing Capability of Sulforaphane Analogues in Human Colon Cancer Cells. M.J. KIM, S.H. KIM, S.-J. LIM (<i>Seoul; Gangneung, South Korea</i>)	3611
A Study of <i>RET</i> Proto-oncogene Polymorphisms in Association with Lung Cancer Risk in the Korean Population. H.K. KIM, H.-Y. JUNG, S. LIM, J. S. SUNG, Y.M. WHANG, U. JO, J. LEE, S.W. SHIN, J.S. KIM, J.S. RYU, Y.H. KIM (<i>Seoul; Incheon, South Korea</i>)	3621
Inhibition of Growth and Induction of Alkaline Phosphatase in Colon Cancer Cells by Flavonols and Flavonol Glycosides. M.A. LEA, C. IBEH, J.K. DEUTSCH, I. HAMID, C. desBORDES (<i>Newark, NJ; Brooklyn, NY, USA</i>)	3629
The Wilms' Tumor Suppressor WT1 Regulates Expression of Members of the Epidermal Growth Factor Receptor (EGFR) and Estrogen Receptor in Acquired Tamoxifen Resistance. L. WANG, X. ZHANG, Z.-Y. WANG (<i>Omaha, NE, USA</i>)	3637
Antiproliferative Effect of LXR Agonists T0901317 and 22(R)- Hydroxycholesterol on Multiple Human Cancer Cell Lines. C.-P. CHUU, H.-P. LIN (<i>Miaoli County, Taiwan, ROC</i>)	3543
Association Study of Cyclooxygenase 2 Single Nucleotide Polymorphisms and Childhood Acute Lymphoblastic Leukemia in Taiwan. C.-H. WANG, K.-H. WU, Y.-L. YANG, C.-T. PENG, R.-F. WANG, C.-W. TSAI, R.-Y. TSAI, D.-T. LIN, F.-J. TSAI, D.-T. BAU (<i>Taichung; Taipei, Taiwan, ROC</i>)	3649
Synergistic Cytotoxic Effects of Arsenic Trioxide plus Dithiothreitol on Mice Oral Cancer Cells. C.-W. TSAI, N.-W. CHANG, R.-Y. TSAI, R.-F. WANG, C.-M. HSU, S.-S. LIN, C.-N. WU, S.-S. SUN, M.-H. TSAI, D.-T. BAU (<i>Taichung, Taiwan, ROC</i>)	3655
The Presence of P-glycoprotein in L1210 Cells Directly Induces Down-Regulation of Cell Surface Saccharide Targets of Concanavalin A. Z. SULOVÁ, P. DITTE, T. KURUCOVÁ, E. POLÁKOVÁ, K. ROGOZANOVÁ, L. GIBALOVÁ, M. ŠEREŠ, L. ŠKVARKOVÁ, J. SEDLÁK, J. PASTOREK, A. BREIER (<i>Bratislava, Slovak Republic</i>)	3661
Modulation of Gemcitabine Accumulation by DNA-Damaging Agents: Mechanisms and Specificity in an <i>In Vitro</i> Model. E. METHAROM, P. GALETTIS, S. MANNERS, M. LINKS (<i>Sydney, Australia</i>)	3669
 <i>Clinical Studies</i> 	
* Review: Novel Chemoradiosensitizers for Cancer Therapy. P. PAGE, L.-X. YANG (<i>San Francisco, CA, USA</i>)	3675
* Review: Active Surveillance for Low-risk Prostate Cancer. R. MAZZUCHELLI, I. NESSERIS, L. CHENG, A. LOPEZ-BELTRAN, R. MONTIRONI, M. SCARPELLI (<i>Ancona, Italy; Indianapolis, IN, USA; Ioannina, Greece; Cordoba, Spain</i>)	3683
* Review: The Evolving Role of Radiofrequency Ablation Therapy of Breast Lesions. B. SOUKUP, S. BISMOHUN, S. REEFY, K. MOKBEL (<i>London, UK</i>)	3693
p27 ^{kip1} Expression in Non-small Cell Lung Cancer Is not an Independent Prognostic Factor. N. SIONVARDY, J. FREEDMAN, I. LAZAROV, A. BOLOTIN, S. ARIAD (<i>Beer Sheva, Israel</i>)	3699
Gastric Tumor from Metastasis of Breast Cancer. D. YAMAMOTO, H. YOSHIDA, K. SUMIDA, Y. UEYAMA, S. KANEMATSU, T. SHOJI, N. SUEOKA, K. TANAKA, Y. TSUBOTA, M. KON (<i>Hirakata, Osaka, Japan</i>)	3705
Immunological Response after Therapeutic Vaccination with <i>WT1</i> mRNA-loaded Dendritic Cells in End-stage Endometrial Carcinoma. A. COOSEMANS, M. WÖLFL, Z.N. BERNEMAN, V. VAN TENDELOO, I. VERGOTE, F. AMANT, S.W. VAN GOOL (<i>Leuven; Antwerp, Belgium; Wuerzburg, Germany</i>)	3709

Optimized Protocols for Generation of Cord Blood-derived Cytokine-induced Killer/Natural Killer Cells. Y. LI, I.G.H. SCHMIDT-WOLF, Y.-F. WU, S.-L. HUANG, J. WEI, J. FANG, K. HUANG, D.-H. ZHOU (Guangzhou, PR China; Bonn, Germany)	3493
Quercetin Inhibits Human DLD-1 Colon Cancer Cell Growth and Polyamine Biosynthesis. M. LINSALATA, A. ORLANDO, C. MESSA, M.G. REFOLO, F. RUSSO (Castellana G., Italy)	3501
Effect of Inhibition of the ROCK Isoform on RT2 Malignant Glioma Cells. N. INABA, S. ISHIZAWA, M. KIMURA, K. FUJIOKA, M. WATANABE, T. SHIBASAKI, Y. MANOME (Tokyo, Japan)	3509
Tumour-Derived Microvesicles (TMV) Mimic the Effect of Tumour Cells on Monocyte Subpopulations. M. BAJ-KRZYWORZEKA, J. BARAN, K. WEGLARCZYK, R. SZATANEK, A. SZAFLARSKA, M. SIEDLAR, M. ZEMBALA (Cracow, Poland)	3515
Expression of Metalloproteinases MMP-2 and MMP-9 in Sentinel Lymph Node and Serum of Patients with Metastatic and Non-Metastatic Breast Cancer. A. DANIELE, A.F. ZITO, G. GIANNELLI, R. DIVELLA, M. ASSELT, A. MAZZOCCA, A. PARADISO, M. QUARANTA (Bari, Italy)	3521
Differential Expression of mTOR Signalling Components in Drug Resistance in Ovarian Cancer. H. FOSTER, H.M. COLEY, A. GOUMENOU, G. PADOS, A. HARVEY, E. KARTERIS (Uxbridge; Guildford, UK; Heraklion; Thessaloniki, Greece)	3529
Decreased Srcasm Expression in Esophageal Squamous Cell Carcinoma in a Chinese Population. Y. QI, X. LI, L. ZHAO, J.T. SEYKORA (Zhengzhou, Henan, PR China; Philadelphia, PA, USA)	3535
Prognostic Relevance of the Proliferation Marker REPP86 for Laryngeal Cancer. C. CORDES, A.-K. MÜNDEL, T. GÖRÖGH, I. LEUSCHNER, P. AMBROSCH, S. GOTTSCHLICH, M. HOFFMANN (Kiel, Germany)	3541
<i>Houttuynia cordata</i> Thunb Extract Inhibits Cell Growth and Induces Apoptosis in Human Primary Colorectal Cancer Cells. K.-C. LAI, Y.-J. CHIU, Y.-J. TANG, K.-L. LIN, J.-H. CHIANG, Y.-L. JIANG, H.-F. JEN, Y.-H. KUO, S. AGAMAYA, J.-G. CHUNG, J.-S. YANG (Yunlim; Taichung; Tainan, Taiwan, ROC; Saitama, Japan)	3549
Increasing P53 Protein Sensitizes Non-Small Cell Lung Cancer to Paclitaxel and Cisplatin <i>In Vitro</i> . V.P. GUNTUR, J.C. WALDREP, J.J. GUO, K. SELTING, R. DHAND (Columbia, MO; Ft. Detrick, MD, USA)	3557
Inhibition of Heat-shock Protein 27 Expression Eliminates Drug Resistance of Osteosarcoma to Zoledronic Acid. T. MORII, K. OHTSUKA, H. OHNISHI, K. MOCHIZUKI, K. SATOMI (Mitaka, Tokyo, Japan)	3565
Significant Association of Methylenetetrahydrofolate Reductase Single Nucleotide Polymorphisms with Prostate Cancer Susceptibility in Taiwan. H.-C. WU, C.-H. CHANG, R.-Y. TSAI, C.-H. LIN, R.-F. WANG, C.-W. TSAI, K.-B. CHEN, C.-H. YAO, C.-F. CHIU, D.-T. BAU, C.-C. LIN (Taichung, Taiwan, ROC)	3573
Importance of miR-20a Expression in Prostate Cancer Tissue. M. PESTA, J. KLECKA, V. KULDA, O. TOPOLCAN, M. HORA, V. ERET, M. LUDVIKOVA, M. BABJUK, K. NOVAK, J. STOLZ, L. HOLUBEC (Pilsen; Prague, Czech Republic)	3579
Effect of Ha-ras ^{val12} on nm23 Expression, Tumor Formation and Metastasis of the Transformants, and Immunomodulation in Tumor-bearing Mice. C.-C. HSIEH, S.-Y. WU, S.-H. LAN, T.-Y. WENG, Y. TSAI, H.-S. LIU (Taichung; Tainan, Taiwan, ROC)	3585
Down-regulation of P-Glycoprotein Is Associated with Resistance to Cisplatin and VP-16 in Human Lung Cancer Cell Lines. J. WANG, H. WANG, L. ZHAO, S. FAN, Z. YANG, F. GAO, L. CHEN, G.G. XIAO, J. MOLNÁR, Q. WANG (Dalian; Shijiazhuang, PR China; Omaha, NE, USA; Szeged, Hungary)	3593
A Dihydroxy-pentamethoxyflavone from <i>Gardenia obtusifolia</i> Suppresses Proliferation and Promotes Apoptosis of Tumor Cells Through Modulation of Multiple Cell Signaling Pathways. K. PHROMNOI, S. REUTER, B. SUNG, P. LIMTRAKUL, B.B. AGGARWAL (Houston, TX, USA; Chiang Mai, Thailand)	3599

The Effect of Bevacizumab on Tumour Growth of Malignant Fibrous Histiocytoma in an Animal Model. Y. OKADA, T. AKISUE, H. HARA, K. KISHIMOTO, T. KAWAMOTO, M. IMABORI, S.-I. KISHIMOTO, N. FUKASE, Y. ONISHI, M. KUROSAKA (<i>Kobe; Akashi, Hyogo, Japan</i>)	3391
Novel Anti-Tn Single-Chain Fv-Fc Fusion Proteins Derived from Immunized Phage Library and Antibody Fc Domain. T. KUBOTA, T. MATSUSHITA, R. NIWA, I. KUMAGAI, K. NAKAMURA (<i>Tokyo; Sendai, Japan</i>)	3397
Jun Amino-terminal Kinase 1 Activation Promotes Cell Survival in ErbB2-Positive Breast Cancer. J.S. HAN, D.L. CROWE (<i>Chicago, IL, USA</i>)	3407
Human Kallikrein 7 Induces Epithelial–Mesenchymal Transition-like Changes in Prostate Carcinoma Cells: A Role in Prostate Cancer Invasion and Progression. L. MO, J. ZHANG, J. SHI, Q. XUAN, X. YANG, M. QIN, C. LEE, H. KLOCKER, Q.Q. LI, Z. MO (<i>Nanning; Tianjin, P. R. China; Chicago, IL; Bethesda, MD, USA; Innsbruck, Austria</i>).....	3413
Cytoplasmic Phospholipase A ₂ Metabolites Play a Critical Role in Pulmonary Tumor Metastasis in Mice. W.C. JEONG, K.-J. KIM, H.-W. JU, H.-K. BACK, H.K. KIM, S.-Y. IM, H.-K. LEE (<i>Seoul; Jeonju; Gwanju, Republic of Korea</i>)	3421
Inhibitory Effect of <i>Cordyceps sinensis</i> on Experimental Hepatic Metastasis of Melanoma by Suppressing Tumor Cell Invasion. E. KUBO, N. YOSHIKAWA, M. KUNITOMO, S. KAGOTA, K. SHINOZUKA, K. NAKAMURA (<i>Nishinomiya, Hyogo, Japan</i>)	3429
Frequency and Role of HPV in the Progression of Epithelial Dysplasia to Oral Cancer. F. ANGIERO, L. BENERINI GATTA, R. SERAMONDI, A. BERENZI, A. BENETTI, S. MAGISTRO, P. ORDESI, P. GRIGOLATO, E. DESSY (<i>Milan; Brescia, Italy</i>)	3435
<i>MCC 1</i> as a Marker for Peritoneal-disseminated Gastric Carcinoma. A. SHIRAHATA, M. SAKATA, Y. KITAMURA, K. SAKURABA, K. YOKOMIZO, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIGAWA, H. NEMOTO, K. HIBI (<i>Yokohama, Japan</i>)	3441
Sporadic Breast Carcinomas with Somatic <i>BRCA1</i> Gene Deletions Share Genotype/Phenotype Features with Familial Breast Carcinomas. K. RHIEM, U. TODT, B. WAPPENSCHMIDT, A. KLEIN, E. WARDELMANN, R.K. SCHMUTZLER (<i>Cologne; Bonn, Germany</i>)	3445
Caveolin-1 and Doxorubicin-induced P-Glycoprotein Modulate Plasma Cholesterol Membrane Accessibility in Erythrolymphoblastic Cell Line. M. ZHU, L. LE MOYEC, A. STARZEC, V. STIERLE, C. MARBEUF-GUEYE (<i>Bobigny; Reims, France</i>).....	3451
TGF-β1 Antisense Impacts the SMAD Signalling System in Fibroblasts from Keloid Scars. G.M. BRAN, U.J. SOMMER, U.R. GOESSLER, K. HÖRMANN, F. RIEDEL, H. SADICK (<i>Mannheim, Germany</i>).....	3459
Down-regulation of Heat-shock Protein 70 (HSP-70) Correlated with Responsiveness to Neoadjuvant Aromatase Inhibitor Therapy in Breast Cancer Patients. C.C.P. YIU, N. CHANPLAKORN, M.S.M. CHAN, W.T.Y. LOO, L.W.C. CHOW, M. TOI, H. SASANO (<i>Sendai; Kyoto, Japan; Hong Kong; Bangkok, Thailand</i>)	3465
Epstein-Barr Virus-infected Cell Line TCC36B Derived from B Lymphocytes Infiltrating Renal Pelvis Urothelial Carcinoma. C.-K. CHUANG, K.-L. CHUANG, C.-H. HSIEH, Y.-C. SHEN, S.-K. LIAO (<i>Taoyuan; Taipei, Taiwan, ROC</i>)	3473
KITENIN Is Associated with Tumor Progression in Human Gastric Cancer. H.-S. RYU, Y.-L. PARK, S.-J. PARK, J.-H. LEE, S.-B. CHO, W.-S. LEE, I.-J. CHUNG, K.-K. KIM, K.-H. LEE, S.-S. KWEON, Y.-E. JOO (<i>Gwangju; Namwon; Jeonnam, South Korea</i>)	3479
Two Multidrug-resistance (<i>ABC1</i>) Gene Polymorphisms as Prognostic Parameters in Women with Ovarian Cancer. C. GRIMM, S. POLTERAUER, R. ZEILLINGER, D. TONG, G. HEINZE, A. WOLF, C. NATTER, A. REINTHALLER, L.A. HEFLER (<i>Vienna, Austria</i>)	3487

The Role of Akt Activation in the Response to Chemotherapy in Pancreatic Cancer. C.M. PARSONS, D. MUILENBURG, T.L. BOWLES, S. VIRUDACHALAM, R.J. BOLD (<i>Sacramento, CA, USA</i>)	3279
GFP-Fluorescence-guided UVC Irradiation Inhibits Melanoma Growth and Angiogenesis in Nude Mice. M.-H. TSAI, R. AKI, Y. AMOH, R.M. HOFFMAN, K. KATSUOKA, H. KIMURA, C. LEE, C.-H. CHANG (<i>Kaohsiung, Taiwan; San Diego; Upland, CA, USA; Sagamihara, Kanagawa; Kanazawa, Ishikawa, Japan</i>) ..	3291
NF- κ B Inhibitors from <i>Brucea javanica</i> Exhibiting Intracellular Effects on Reactive Oxygen Species. J.-A. KIM, E.K. LAU, L. PAN, E.J. CARCACHE DE BLANCO (<i>Columbus, OH, USA</i>)	3295
Maturation of Tumor Vasculature by Interferon- β Disrupts the Vascular Niche of Glioma Stem Cells. R.F. WILLIAMS, T.L. SIMS, L. TRACEY, A.L. MYERS, C.Y.C. NG, H. POPPLETON, A.C. NATHWANI, A.M. DAVIDOFF (<i>Memphis, TN, USA; London, UK</i>)	3301
Evidence for a Tumour Suppressor Function of SETD2 in Human Breast Cancer: A New Hypothesis. R.F. NEWBOLD, K. MOKBEL (<i>Uxbridge, Middlesex, UK</i>)	3309
Increased Expression of Macrophage Migration Inhibitory Factor During Progression to Hypopharyngeal Squamous Cell Carcinoma. S. CLUDTS, C. DECAESTECKER, B. JOHNSON, J. LECHIEN, X. LEROY, N. KINDT, H. KALTNER, S. ANDRÉ, H.-J. GABIUS, S. SAUSSEZ (<i>Mons; Brussels, Belgium; Milwaukee, WI, USA; Lille, France; Munich, Germany</i>)	3313
Efficacy of MDM2 Inhibitor MI-219 Against Lung Cancer Cells Alone or in Combination with MDM2 Knockdown, a XIAP Inhibitor or Etoposide. M. ZHENG, J. YANG, X. XU, J.T. SEBOLT, S. WANG, Y. SUN (<i>Ann Arbor, MI; San Diego, CA, USA</i>)	3321
Growth Inhibitory and Apoptosis-inducing Effects of Xanthohumol, a Prenylated Chalone Present in Hops, in Human Prostate Cancer Cells. D. DEEB, X. GAO, H. JIANG, A.S. ARBAB, S.A. DULCHAVSKY, S.C. GAUTAM (<i>Detroit, MI, USA</i>)	3333
Some Considerations for the Study of TGF β in Medium of Irradiated T98G Cells: Activation, Release and Consumption. A. FACOETTI, F. PASI, R. NANO (<i>Pavia, Italy</i>)	3341
Effect of a Neurokinin-1 Receptor Antagonist in a Rat Model of Colitis-Associated Colon Cancer. B. PAGÁN, A.A. ISIDRO, D. COPPOLA, Z. CHEN, Y. REN, J. WU, C. B. APPELYARD (<i>Ponce, PR; Tampa, FL, USA</i>)	3345
Sunitinib (SU11248) Inhibits Growth of Human Ovarian Cancer in Xenografted Mice. D.O. BAUERSCHLAG, C. SCHEM, S. TIWARI, J.H. EGBERTS, M.T. WEIGEL, H. KALTHOFF, W. JONAT, N. MAASS, I. MEINHOLD-HEERLEIN (<i>Aachen; Kiel, Germany</i>)	3355
Sonodynamically Induced Cell Damage Using Rose Bengal Derivative. N. SUGITA, Y. IWASE, N. YUMITA, T. IKEDA, S.-I. UMEMURA (<i>Tokyo; Kanagawa; Miyaki, Japan</i>)	3361
Identification of Up- and Down-regulated Proteins in Gemcitabine-resistant Pancreatic Cancer Cells Using Two-dimensional Gel Electrophoresis and Mass Spectrometry. Y. KURAMITSU, K. TABA, S. RYOZAWA, K. YOSHIDA, X. ZHANG, T. TANAKA, S.-I. MAEHARA, Y. MAEHARA, I. SAKAIDA, K. NAKAMURA (<i>Yamaguchi; Fukuoka, Japan</i>)	3367
Influence of Structural Variations on Biological Activity of Anti-PSMA scFv and Immunotoxins Targeting Prostate Cancer. P. BÜHLER, D. WETTERAUER, D. GIERSCHNER, U. WETTERAUER, U. ELSÄSSER BEILE, P. WOLF (<i>Freiburg, Germany</i>)	3373
Autophagy Inhibition Enhances Sulforaphane-induced Apoptosis in Human Breast Cancer Cells. S. KANEMATSU, N. UEHARA, H. MIKI, K. YOSHIZAWA, A. KAWANAKA, T. YURI, A. TSUBURA (<i>Osaka, Japan</i>)	3381